These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 25122664)

  • 41. Risk Factors for Suboptimal Utilization of Statins and Antiplatelet Therapy in Patients Undergoing Revascularization for Symptomatic Peripheral Arterial Disease.
    Meltzer AJ; Sedrakyan A; Connolly PH; Ellozy S; Schneider DB;
    Ann Vasc Surg; 2018 Jan; 46():234-240. PubMed ID: 28602895
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictors, Trends, and Outcomes (Among Older Patients ≥65 Years of Age) Associated With Beta-Blocker Use in Patients With Stable Angina Undergoing Elective Percutaneous Coronary Intervention: Insights From the NCDR Registry.
    Motivala AA; Parikh V; Roe M; Dai D; Abbott JD; Prasad A; Mukherjee D
    JACC Cardiovasc Interv; 2016 Aug; 9(16):1639-48. PubMed ID: 27539683
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Optimal Medical Therapy in Patients with Malignancy Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome: a BleeMACS Sub-Study.
    Iannaccone M; D Ascenzo F; De Filippo O; Gagliardi M; Southern DA; Raposeiras-Roubín S; Abu-Assi E; Henriques JPS; Saucedo J; González-Juanatey JR; Wilton SB; Kikkert WJ; Nuñez-Gil I; Ariza-Sole A; Song X; Alexopoulos D; Liebetrau C; Kawaji T; Huczek Z; Nie SP; Fujii T; Correia L; Kawashiri MA; García-Acuña JM; Alfonso E; Terol B; Garay A; Zhang D; Chen Y; Xanthopoulou I; Osman N; Möllmann H; Shiomi H; Kowara M; Filipiak K; Wang X; Yan Y; Fan JY; Ikari Y; Nakahashi T; Sakata K; Yamagishi M; Moretti C; Gaita F; Kalpak O; Kedev S
    Am J Cardiovasc Drugs; 2017 Feb; 17(1):61-71. PubMed ID: 27738920
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Utilization of secondary prevention therapies in patients with nonobstructive coronary artery disease identified during cardiac catheterization: insights from the National Cardiovascular Data Registry Cath-PCI Registry.
    Maddox TM; Ho PM; Roe M; Dai D; Tsai TT; Rumsfeld JS
    Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):632-41. PubMed ID: 20923997
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Coronary artery disease performance measures and statin use in patients with recent percutaneous coronary intervention or recent coronary artery bypass grafting (from the NCDR PINNACLE registry).
    Bandeali SJ; Gosch K; Alam M; Kayani WT; Jneid H; Fiocchi F; Wilson JM; Chan PS; Deswal A; Maddox TM; Virani SS
    Am J Cardiol; 2015 Apr; 115(8):1013-8. PubMed ID: 25721483
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of Long-Term Mortality in Patients With Previous Coronary Artery Bypass Grafting Who Underwent Percutaneous Coronary Intervention With Versus Without Optimal Medical Therapy.
    Nakamura Y; Asaumi Y; Miyagi T; Nakai M; Nishimura K; Sugane H; Matama H; Kataoka Y; Miyamoto Y; Takeishi Y; Noguchi T; Yasuda S
    Am J Cardiol; 2018 Jul; 122(2):206-212. PubMed ID: 29747859
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Validation of the appropriate use criteria for percutaneous coronary intervention in patients with stable coronary artery disease (from the COURAGE trial).
    Bradley SM; Chan PS; Hartigan PM; Nallamothu BK; Weintraub WS; Sedlis SP; Dada M; Maron DJ; Kostuk WJ; Berman DS; Teo KK; Mancini GB; Boden WE; Spertus JA
    Am J Cardiol; 2015 Jul; 116(2):167-73. PubMed ID: 25960375
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reasons for not prescribing guideline-recommended medications to adults with heart failure.
    Steinman MA; Dimaano L; Peterson CA; Heidenreich PA; Knight SJ; Fung KZ; Kaboli PJ
    Med Care; 2013 Oct; 51(10):901-7. PubMed ID: 23969589
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The application status of optimal medical therapy after percutaneous coronary intervention and its influence on prognosis].
    Zhang J; Jing R; Liu JJ; Di CY; Lu YJ; Gao P; Wang YJ; Yang RF; Lin WH
    Zhonghua Yi Xue Za Zhi; 2021 Apr; 101(15):1064-1070. PubMed ID: 33878833
    [No Abstract]   [Full Text] [Related]  

  • 50. Secondary prevention in coronary heart disease: goal achievement and drug prescribing.
    Giverhaug T; Bruland C; Trovik T
    Pharm World Sci; 2005 Dec; 27(6):472-4. PubMed ID: 16341957
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Temporal Trends in Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting: Insights From the Washington Cardiac Care Outcomes Assessment Program.
    Kataruka A; Maynard CC; Kearney KE; Mahmoud A; Bell S; Doll JA; McCabe JM; Bryson C; Gurm HS; Jneid H; Virani SS; Lehr E; Ring ME; Hira RS
    J Am Heart Assoc; 2020 Jun; 9(11):e015317. PubMed ID: 32456522
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [SECONDARY PREVENTION IN PATIENTS WITH ACUTE CORONARY SYNDROME HOSPITALIZED IN INTERNAL MEDICINE DEPARTMENTS].
    Yahia DH; Pereg D; Lishner M; Elis A
    Harefuah; 2015 May; 154(5):299-302, 339-40. PubMed ID: 26168639
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study.
    Resor CD; Nathan A; Kereiakes DJ; Yeh RW; Massaro JM; Cutlip DE; Gabriel Steg P; Hsieh WH; Mauri L;
    Circulation; 2016 Oct; 134(14):989-998. PubMed ID: 27576774
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of a smartphone-based intervention on secondary prevention medication prescriptions after coronary artery bypass graft surgery: The MISSION-1 randomized controlled trial.
    Qu J; Du J; Rao C; Chen S; Gu D; Li J; Zhang H; Zhao Y; Hu S; Zheng Z;
    Am Heart J; 2021 Jul; 237():79-89. PubMed ID: 33689732
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of Optimal Medical Therapy at Discharge on One-year Direct Medical Costs in Patients with Acute Coronary Syndromes: A Retrospective, Observational Database Analysis in China.
    He X; Wang Y; Cong H; Lu C; Wu J
    Clin Ther; 2019 Mar; 41(3):456-465.e2. PubMed ID: 30770126
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Survival benefit from recent changes in management of men and women with ST-segment elevation myocardial infarction treated with percutaneous coronary interventions.
    Zandecki Ł; Sadowski M; Janion M; Kurzawski J; Gierlotka M; Poloński L; Gąsior M
    Cardiol J; 2019; 26(5):459-468. PubMed ID: 29924379
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Underuse of cardioprotective medications in patients prior to acute myocardial infarction.
    Miller RR; Li YF; Sun H; Kopjar B; Sales AE; Piñeros SL; Fihn SD
    Am J Cardiol; 2003 Jul; 92(2):209-11. PubMed ID: 12860227
    [No Abstract]   [Full Text] [Related]  

  • 58. ACE up the sleeve - are vascular patients medically optimized?
    Coveney AP; O'Brien GC; Fulton GJ
    Vasc Health Risk Manag; 2011 Jan; 7():15-21. PubMed ID: 21339909
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trial.
    Teo KK; Sedlis SP; Boden WE; O'Rourke RA; Maron DJ; Hartigan PM; Dada M; Gupta V; Spertus JA; Kostuk WJ; Berman DS; Shaw LJ; Chaitman BR; Mancini GB; Weintraub WS;
    J Am Coll Cardiol; 2009 Sep; 54(14):1303-8. PubMed ID: 19778673
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fractional flow reserve-guided PCI for stable coronary artery disease.
    De Bruyne B; Fearon WF; Pijls NH; Barbato E; Tonino P; Piroth Z; Jagic N; Mobius-Winckler S; Rioufol G; Witt N; Kala P; MacCarthy P; Engström T; Oldroyd K; Mavromatis K; Manoharan G; Verlee P; Frobert O; Curzen N; Johnson JB; Limacher A; Nüesch E; Jüni P;
    N Engl J Med; 2014 Sep; 371(13):1208-17. PubMed ID: 25176289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.